AstraZeneca (AZN) Has Supplied Two Billion Doses of COVID-19 Vaccine in 11 Months
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
New Data Phase 3 Data Confirms Robust Efficacy and Long-Term Prevention Effects of AstraZeneca (AZN) AZD7442
November 18, 2021 5:10 AM ESTAstraZeneca (NASDAQ: AZN) reports new data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials, with both demonstrating robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
In an analysis of the ongoing PROVENT trial evaluating a median six months of participant follow-up, one 300mg IM dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.
About 2% of the global population is considered at increased risk of an inadequate response to a COVID-19 vaccine.1 This includes people with blood... More
Credit Suisse Reiterates Outperform Rating on AstraZeneca (AZN:LN) (AZN)
November 16, 2021 5:09 AM ESTCredit Suisse analyst Trung Huynh reiterated an Outperform rating and GBP90.00 price target on AstraZeneca (AZN:LN) (NASDAQ: AZN).
... MoreBarclays Reiterates Overweight Rating on AstraZeneca (AZN:LN) (AZN)
November 15, 2021 8:29 AM ESTBarclays analyst Emily Field reiterated an Overweight rating and GBP110.00 price target on AstraZeneca (AZN:LN) (NASDAQ: AZN).
... MoreAstraZeneca (AZN) Reports Positive Phase IIa Results from the EPICCURE Trial
November 15, 2021 8:24 AM ESTAstraZeneca (NASDAQ: AZN) announces positive Phase IIa results from the EPICCURE trial, demonstrating that AZD8601 met the primary endpoint of safety and tolerability in patients with heart failure.
In the trial, researchers injected mRNA encoding vascular endothelial growth factor (VEGF-A) known as AZD8601 directly into the myocardium of patients undergoing elective coronary artery bypass surgery (CABG) surgery. AZD8601 is being co-developed with Moderna.
In the study... More
UBS Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
November 15, 2021 4:45 AM ESTUBS analyst Michael Leuchten reiterated a Buy rating and GBP100.00 price target on AstraZeneca (AZN:LN) (NASDAQ: AZN).
... MoreIncreasing unusual put option volume: WEN EVGO MQ MAPS SNDL AZN SFT BLNK
November 12, 2021 10:04 AM ESTIncreasing unusual put option volume: WEN EVGO MQ MAPS SNDL AZN SFT BLNK
... MoreAstraZeneca (AZN) Reports Q3 Core EPS of $1.08, Revenues of $9.87B
November 12, 2021 5:30 AM ESTAstraZeneca (NASDAQ: AZN) reported Q3 Core EPS of $1.08. Revenue for the quarter came in at $9.87 billion versus the consensus estimate of $9.87 billion.
GUIDANCE:
AstraZeneca sees FY2021 Core EPS of $5.05-$5.40, versus the consensus of $3.27.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
... MoreAstraZeneca starts to make modest profit from COVID-19 vaccine
November 12, 2021 2:33 AM ESTBy Pushkala Aripaka and Ludwig Burger
(Reuters) - AstraZeneca said it would begin to earn a modest profit from its coronavirus vaccine as the world learns to live with the virus and the drugmaker is in talks with several countries about new orders for delivery next year.
AstraZeneca made a commitment to sell the shot developed with Oxford University at cost during the pandemic and in a press conference on Friday said low-income nations would continue to receive the vaccine on a no-profit basis, while a post-pandemic commercial approach would apply to other new orders even as... More
